Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Ning Jiang
Institutions:
Jiangsu Cancer Hospital,
Nanjing Medical University
Observed institutions:
Jiangsu Cancer Hospital,
Nanjing Medical University
ORCID:
0000-0003-3145-9570
Observed ORCID:
0000-0003-3145-9570
OpenAlex ID:
A5058750573
Short-course neoadjuvant radiotherapy combined with chemotherapy and toripalimab for locally advanced esophageal squamous cell carcinoma (SCALE-1): a single-arm phase Ib clinical trial
2024
·
Ning Jiang
, Jingyuan Zhang
, et al.
·
Journal for ImmunoTherapy of Cancer
·
36
PDF
SCALE-1: Safety and efficacy of short course neoadjuvant chemo-radiotherapy plus toripalimab for locally advanced resectable squamous cell carcinoma of esophagus.
2022
·
Ning Jiang
, Ming Jiang
, et al.
·
Journal of Clinical Oncology
·
16
Impact of neoadjuvant immunotherapy combined with chemotherapy or chemoradiotherapy on postoperative safety in locally advanced esophageal squamous cell carcinoma: a propensity score-matched retrospective cohort study
2025
·
Yixin Li
, Gang Xiao
, et al.
·
Frontiers in Oncology
·
5
PDF
Complete responses after neoadjuvant toripalimab and chemoradiotherapy for oesophageal squamous cell carcinoma: in situ and ex vivo 3.0 T MRI assessment
2023
·
Lijun Zhao
, Xiangzhi Zhu
, et al.
·
British journal of surgery
·
2
PDF
Neoadjuvant immunochemotherapy with or without radiotherapy for locally advanced esophageal squamous cell carcinoma: a pooled analysis of two prospective single-arm clinical trials
2026
·
Yixin Li
, Ming Jiang
, et al.
·
International Journal of Surgery
·
1
Association between germ-line HLA and immune-related adverse events.
2022
·
Ning Jiang
, Yue Yu
, et al.
·
Journal of Clinical Oncology
·
1
Low-Dose Stereotactic Body Radiation Therapy–Based Radiation Therapy Followed by Pembrolizumab and Chemotherapy for Potentially Resectable Non-Small Cell Lung Cancer: A Phase 1b Study
2026
·
Xiangzhi Zhu
, Lijun Zhao
, et al.
·
International Journal of Radiation Oncology*Biology*Physics
Induction chemoimmunotherapy followed by hypofractionated radiotherapy and consolidation immunotherapy for locally advanced unresectable non–small cell lung cancer: A prospective phase II study.
2026
·
Xiangzhi Zhu
, Lijun Zhao
, et al.
·
Journal of Clinical Oncology
SCALE-2: A phase 2 trial evaluating neoadjuvant short-course radiotherapy combined with chemotherapy and toripalimab in resectable locally advanced esophageal squamous cell carcinoma.
2026
·
Ning Jiang
, Xiangzhi Zhu
, et al.
·
Journal of Clinical Oncology
PDF
Tislelizumab plus short-course chemo-radiotherapy for conversion therapy of unresectable ESCC (LATE): A proof-of-concept, phase Ib trial.
2025
·
Ning Jiang
, Ming Jiang
, et al.
·
Journal of Clinical Oncology
Evaluating the efficacy of chemoradiotherapy combined with immunotherapy for local-regional recurrent esophageal cancer patients after esophagectomy: A retrospective analysis.
2024
·
Qicen Xu
, Dongjie Feng
, et al.
·
Journal of Clinical Oncology
Safety and efficacy of radiotherapy in combination with immunochemotherapy for advanced esophageal cancer: A retrospective analysis.
2024
·
Yu Chen
, Ting Qian
, et al.
·
Journal of Clinical Oncology
Impact of immunotherapy combined with neoadjuvant chemotherapy or chemoradiotherapy on perioperative safety in locally advanced esophageal squamous cell carcinoma (LA-ESCC): A retrospective propensity score-matched analysis.
2024
·
Yixin Li
, Gang Xiao
, et al.
·
Journal of Clinical Oncology
ZNF488 Enhances the Invasion and Metastasis through Activating the MAPK/ERK Signaling Pathway in Non-Small Cell Lung Cancer
2021
·
Yu-feng Zhang
, Huan-feng Zhu
, et al.
·
Research Square
PDF
Show more works
View as search
Works count:
14
Citation count:
61
H-index:
3
I10-index:
2
Year
Topic
Type